Citations

Showing 10 of 108152 citations.

Heart failure in pregnancy: what is the long-term impact of pregnancy on cardiac function? A tertiary care centre experience and systematic review
Dodeja, Anudeep K. , Siegel, Francesca, Dodd, Katherine, Ma’ayeh, Marwan , Fuchs, Margaret , Mah, May Ling , Bradley, Elisa A. , Fuchs, Margaret M , Bradley, Elisa A , Mehta, Laxmi S. , Rood, Kara M.

Mayo Clinic

Open Heart | August 3, 2021 | Volume: 8 | Issue: 2 | Pages: e001587

10.1136/openhrt-2021-001587 | PMID 34344721 Get It

Background Women with cardiomyopathy (CM) are often advised against pregnancy due to risk for major adverse cardiovascular events (MACE). However, the impact of CM subtype on maternal MACE is not understood, and so we sought to evaluate the influence of CM phenotype on maternal outcomes, as well as the effect on immediate and late left ventricular function. Methods We evaluated all pregnant women in our high-risk maternal cardiovascular programme (2009–2019). Composite maternal MACE included: death, inotrope use, left ventricular assist device, orthotopic heart transplant and/or escalation in transplant listing status, acute decompensated heart failure and sustained ventricular arrhythmia. Results Among 875 women followed, 32 had CM (29±7 years old, left ventricular ejection fraction (LVEF) 41%±12%): 3 ischaemic CM (ICM), 10 peripartum CM (PPCM) and 19 non-ICM (NICM). MACE events occurred in 6 (18%) women (PPCM: 2 (33%), NICM: 4 (67%)). There was no difference in LVEF at baseline, however, women with MACE had significantly lower LVEF both early (LVEF: 27±5% vs . 41±2%, p<0.05) and late post partum (LVEF: 28±5% vs . 44±2%, p<0.01). Conclusions In this contemporary cohort of women with CM, maternal MACE rates were lower than previously reported, and were less common in PPCM as compared with ICM and NICM. Heart function in women with MACE was negatively impacted immediately after delivery and in late postpartum follow-up, suggesting that pregnancy itself likely has influence on future left ventricular function in women with underlying CM.
Short reply to “Proton therapy for newly diagnosed glioblastoma: more room for investigation” by R. Press et al
Chung, Caroline , Brown, Paul D. , Wefel, Jeffrey S.

Mayo Clinic

Neuro-Oncology | August 3, 2021 | Volume: 23 | Issue: 11 | Pages: 1982-1982

10.1093/neuonc/noab193 | PMID 34453547 Get It

Clinical and histopathological features of adult patients with dermatomyositis and melanoma differentiation associated‐5 autoantibody seropositivity status, as determined by commercially available testing: a retrospective, single‐institution comparative co
Shakshouk, Hadir , Deschaine, Maria , Wetter, David A. , Drage, L.A., Ernste, Floranne C. , Lehman, Julia S. , Shakshouk, H , Lehman, Julia S

Mayo Clinic

Clinical and Experimental Dermatology | August 3, 2021 | Volume: 47 | Issue: 2 | Pages: 282-288

10.1111/ced.14870 | PMID 34342883 Get It

Clinical, pathological and genetic characteristics of Perry disease—new cases and literature review
Dulski, Jarosław , Cerquera‐Cleves, Catalina , Milanowski, Łukasz , Kidd, Alexa, Sitek, Emilia J. , Strongosky, Audrey , Monroy, Ana María Vanegas, Ross, Owen A. , Pentela‐Nowicka, Jolanta, Wszolek, Z.K. , Ross, Owen A , Milanowski, Łukasz M , Dulski, Jaroslaw , Monroy, Ana Maria Vanegas , Dickson, Dennis W. , Sławek, Jarosław , Wszołek, Zbigniew K.

Mayo Clinic

European Journal of Neurology | August 3, 2021 | Volume: 28 | Issue: 12 | Pages: 4010-4021

10.1111/ene.15048 | PMID 34342072 Get It

AbstractBackground and purposePerry disease (or Perry syndrome) is an autosomal dominant neurodegenerative disorder characterized by parkinsonism, neuropsychiatric symptoms, central hypoventilation, weight loss and distinct TDP‐43 pathology. It is caused by mutations of the DCTN1 gene encoding an essential component of axonal transport. The objectives were to provide the current state of knowledge on clinical, pathological and genetic aspects of Perry disease, as well as practical suggestions for the management of the disease.MethodsData on new patients from New Zealand, Poland and Colombia were collected, including autopsy report. Also all of the published papers since the original work by Perry in 1975 were gathered and analyzed.ResultsParkinsonism was symmetrical, progressed rapidly and was poorly responsive to L‐Dopa; nonetheless, a trial with high doses of L‐Dopa is warranted. Depression was severe, associated with suicidal ideations, and benefited from antidepressants and L‐Dopa. Respiratory symptoms were the leading cause of death, and artificial ventilation or a diaphragm pacemaker prolonged survival. Weight loss occurred in most patients and was of multifactorial etiology. Autonomic dysfunction was frequent but underdiagnosed. There was a clinical overlap with other neurodegenerative disorders. An autopsy showed distinctive pallidonigral degeneration with TDP‐43 pathology. Genetic testing provided evidence of a common founder for two families. There was striking phenotypic variability in DCTN1‐related disorders. It is hypothesized that oligogenic or polygenic inheritance is at play.ConclusionsPerry disease and other DCTN1‐related diseases are increasingly diagnosed worldwide. Relatively effective symptomatic treatments are available. Further studies are needed to pave the way toward curative/gene therapy.
MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology
Mallipeddi, Nipun , Ghoshal, Nupur , Wright, Brenton A. , Day, Gregory S. , Davis, Albert A. , Kim, Albert H. , Zipfel, Gregory J. , Bateman, Randall J. , Gabelle, Audrey , Barthélemy, Nicolas R. , Sato, Chihiro , Mallipeddi, Nipun , Ghoshal, Nupur , Wright, Brenton A , Day, Gregory S , Davis, Albert A , Kim, Albert H , Zipfel, Gregory J , Bateman, Randall J , Gabelle, Audrey , Barthélemy, Nicolas R

Mayo Clinic

Annals of Clinical and Translational Neurology | August 3, 2021 | Volume: 8 | Issue: 9 | Pages: 1817-1830

10.1002/acn3.51435 | PMID 34342183 Get It

AbstractObjectiveTau hyperphosphorylation at threonine 217 (pT217) in cerebrospinal fluid (CSF) has recently been linked to early amyloidosis and could serve as a highly sensitive biomarker for Alzheimer’s disease (AD). However, it remains unclear whether other tauopathies induce pT217 modifications. To determine if pT217 modification is specific to AD, CSF pT217 was measured in AD and other tauopathies.MethodsUsing immunoprecipitation and mass spectrometry methods, we compared CSF T217 phosphorylation occupancy (pT217/T217) and amyloid‐beta (Aβ) 42/40 ratio in cognitively normal individuals and those with symptomatic AD, progressive supranuclear palsy, corticobasal syndrome, and sporadic and familial frontotemporal dementia.ResultsIndividuals with AD had high CSF pT217/T217 and low Aβ42/40. In contrast, cognitively normal individuals and the majority of those with 4R tauopathies had low CSF pT217/T217 and normal Aβ 42/40. We identified a subgroup of individuals with increased CSF pT217/T217 and normal Aβ 42/40 ratio, most of whom were MAPT R406W mutation carriers. Diagnostic accuracies of CSF Aβ 42/40 and CSF pT217/T217, alone and in combination were compared. We show that CSF pT217/T217 × CSF Aβ 42/40 is a sensitive composite biomarker that can separate MAPT R406W carriers from cognitively normal individuals and those with other tauopathies.InterpretationMAPT R406W is a tau mutation that leads to 3R+4R tauopathy similar to AD, but without amyloid neuropathology. These findings suggest that change in CSF pT217/T217 ratio is not specific to AD and might reflect common downstream tau pathophysiology common to 3R+4R tauopathies.
Diagnostic Imaging of A2 Pulley Injuries: A Review of the Literature
Berrigan, William A. , White, William D. , Cipriano, Kevin , Wickstrom, Jordan , Smith, Jay , Hager, Nelson, White, William

Mayo Clinic

Journal of Ultrasound in Medicine | August 3, 2021 | Volume: 41 | Issue: 5 | Pages: 1047-1059

10.1002/jum.15796 | PMID 34342037 Get It

Injury to the A2 pulley is caused by high eccentric forces on the flexor‐tendon–pulley system. Accurate diagnosis is necessary to identify the most appropriate treatment options. This review summarizes the literature with respect to using ultrasound (US) to diagnose A2 pulley injuries, compares ultrasound to magnetic resonance imaging and computed tomography, and identifies current knowledge gaps. The results suggest that US should be used as the primary imaging modality given high accuracy, relatively low cost, ease of access, and dynamic imaging capabilities. Manual resistance is beneficial to accentuate bowstringing, but further research is needed to determine best positioning for evaluation.
Benefits and Harms of Levothyroxine/L-Triiodothyronine Versus Levothyroxine Monotherapy for Adult Patients with Hypothyroidism: Systematic Review and Meta-Analysis
Millán-Alanís, Juan Manuel , González‐González, José Gerardo , Flores-Rodríguez, Andrea , Ospina, Naykky Singh , Moreno‐Peña, Pablo J. , Brito, Juan P. , Gonzalez‐Velazquez, Camilo , Rodríguez‐Gutiérrez, René , Moreno-Peña, Pablo J, González-Velázquez, Camilo , Rodríguez-Gutiérrez, René , González-González, José Gerardo , Singh Ospina, Naykky , Brito, Juan P , Maraka, Spyridoula

Mayo Clinic

Thyroid® | August 3, 2021 | Volume: 31 | Issue: 11 | Pages: 1613-1625

10.1089/thy.2021.0270 | PMID 34340589 Get It

Background: Combined therapy with levothyroxine (LT4)/L-triiodothyronine (LT3) has garnered attention among clinicians and patients as a potential treatment alternative to LT4 monotherapy. The objective of this study was to compare the benefits and harms of LT4/LT3 combined therapy and LT4 monotherapy for patients with hypothyroidism. Methods: A systematic search in MEDLINE, Scopus, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials was performed by a librarian from inception date until September 2020. Randomized clinical trials and quasiexperimental studies comparing combined therapy (LT4/LT3) versus monotherapy (LT4) for adult patients with hypothyroidism were considered for inclusion. Independent data extraction was performed by paired reviewers. A meta-analysis comparing standardized mean differences of the effect of each therapy was performed on clinical outcomes and patient preferences. Proportions of adverse events and reactions were assessed narratively. Results: A total of 1398 references were retrieved, from which 18 fulfilled the inclusion criteria. Results supported by evidence at low-to-moderate certainty evidence did not display a difference in treatment effect between therapies on clinical status, quality of life, psychological distress, depressive symptoms, and fatigue; all measured with standardized questionnaires. Furthermore, meta-analysis of patient preferences revealed higher proportions of choice for combined therapy (43%) when compared with monotherapy (23%) or having no preference (30%). When evaluating treatment adverse events or adverse reactions, similar proportions were observed between treatment groups; meta-analysis was not possible. Conclusions: The available evidence at low-to-moderate certainty demonstrates that there is no difference in clinical outcomes between LT4/LT3 combined therapy and LT4 monotherapy for treating hypothyroidism in adults, except for a higher proportion of patient preferring combined therapy. Adverse events and reactions appear to be similar across both groups, however, this observation is only narrative. These results could inform shared decision-making conversations between patients with hypothyroidism and their clinicians. PROSPERO Registration ID: CRD42020202658.
Fimepinostat (CUDC‐907) in patients with relapsed/refractory diffuse large B cell and high‐grade B‐cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses
Landsburg, Daniel J. , Ramchandren, Radhakrishnan , Batlevi, Connie Lee , Iyer, Swaminathan P. , Kelly, Kevin R. , Micallef, Ivana N. , Smith, Sonali M. , Stevens, Don A., Alvarez, Mariano J. , Shen, Yao , Bosker, Gideon, Parker, Jefferson, Soikes, Raul, Martinez, Elizabeth , Roemeling, Reinhard von, Martell, Robert E., Oki, Yasuhiro , Landsburg, Daniel J , Barta, Stefan K , Califano, Andrea , Parker, Jefferson

Mayo Clinic

British Journal of Haematology | August 3, 2021 | Volume: 195 | Issue: 2 | Pages: 201-209

10.1111/bjh.17730 | PMID 34341990 Get It

SummaryFimepinostat (CUDC‐907), a first‐in‐class oral small‐molecule inhibitor of histone deacetylase and phosphatidylinositol 3‐kinase, demonstrated efficacy in a phase 1 study of patients with relapsed/refractory (R/R) diffuse large and high‐grade B‐cell lymphomas (DLBCL/HGBL), particularly those with increased MYC protein expression and/orMYCgene rearrangement/copy number gain (MYC‐altered disease). Therefore, a phase 2 study of fimepinostat was conducted in this patient population with 66 eligible patients treated. The primary end‐point of overall response (OR) rate for patients with MYC‐IHC ≥40% (n = 46) was 15%. Subsequently, exploratory pooled analyses were performed including patients treated on both the phase 1 and 2 studies based upon the presence of MYC‐altered disease as well as a biomarker identified by Virtual Inference of Protein activity by Enriched Regulon analysis (VIPER). For these patients with MYC‐altered disease (n = 63), the overall response (OR) rate was 22% with seven responding patients remaining on treatment for approximately two years or longer, and VIPER yielded a three‐protein biomarker classification with positive and negative predictive values of ≥85%. Prolonged durations of response were achieved by patients with MYC‐altered R/R DLBCL/HGBL treated with single‐agent fimepinostat. Combination therapies and/or biomarker‐based patient selection strategies may lead to higher response rates in future clinical trials.
Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review
Chan, David , Bergsland, Emily K. , Chan, Jennifer A. , Gadgil, Rujuta, Hornbacker, Kathleen , Kelly, Virginia, Kunz, Pamela L. , McGarrah, Patrick W. , Raj, Nitya , Reidy‐Lagunes, Diane , Thawer, Alia , Whitman, Julia, Wu, Linda Y. , Becker, Christoph R. , Singh, Simron , Chan, David L , McGarrah, Patrick , Hálfdánarson, Þorvarður R.

Mayo Clinic

The Oncologist | August 3, 2021 | Volume: 26 | Issue: 11 | Pages: 950-955

10.1002/onco.13923 | PMID 34342086 Get It

Abstract Background Grade 3 gastroenteropancreatic neuroendocrine neoplasms (G3 GEPNENs) are often aggressive, and the optimal treatment is unclear for this subgroup of neuroendocrine neoplasms (NENs). Temozolomide (TEM)-based regimens have been increasingly used to treat grade 1–2 NENs, but their efficacy in G3 NENs remains undetermined. We aimed to assess the clinical efficacy of TEM-containing regimens in advanced grade 3 GEPNENs. Materials and Methods A multicenter retrospective review (2008–2018) of patients with metastatic/unresectable G3 GEPNENs who received a TEM-containing regimen was undertaken within a North American partnership to pool data. The primary endpoint was time to treatment failure (TTF). Radiologic response was extracted from local reports. Results One hundred and thirty patients in six high-volume NEN centers were included (median age 55, 64% male, 18% functional, 67% pancreatic NEN). Forty-nine percent were well-differentiated, 35% poorly differentiated, and 15% unknown based on local pathology reports. The regimen used was capecitabine and temozolomide (CAPTEM) in 92% and TEM alone in 8%. Radiological response by local assessment was seen in 36% of patients. Median TTF was 3.6 months and median overall survival (OS) 19.2 months. Six percent of patients required discontinuation of therapy due to adverse events. TTF was longer in first-line treatment (7.8 months vs. 2.9 months; hazard ratio, 1.62; 95% confidence interval, 1.11–2.36; p = .015) and in patients with pancreatic NENs (panNENs) compared with gastrointestinal NENs (5.8 months vs 1.8 months; p = .04). The overall response rate was higher in the first-line setting (51% vs 29%; p = .02) and in panNEN (41% vs 23%; p = .04). Conclusion This is the largest TEM treatment series in G3 NEN, involving collaboration of several major North American NEN centers as a partnership. Thirty-six percent of patients showed some degree of radiographic response, and treatment was generally well tolerated, although the median duration of response was short. Response rates and time to treatment failure were superior in the first-line setting. CAPTEM should be considered a viable treatment option in this setting. Further randomized trials are warranted. Implications for Practice Neuroendocrine neoplasms (NENs) are heterogeneous, and optimal treatment for aggressive grade 3 (G3) NENs remains undetermined. The capecitabine and temozolomide (CAPTEM) regimen has been used in low-grade pancreas NENs but there are few data for its safety and efficacy in the G3 setting. This article reports on the efficacy of temozolomide-containing regimens, particularly CAPTEM, in management of G3 NENs. The good tolerance and response rate show that CAPTEM should be considered a viable regimen in treatment of G3 NENs pending confirmatory prospective studies.
Development of the National Otolaryngology Interest Group: Conception to Implementation
Farsar, Cameron J., Sperling, Jared A., Quesada, P , Solis, Roberto N. , Ojeaga, Macaulay , Carlson, Matthew L. , Sperling, Jared, Bowe, Sarah N. , Brown, Jason R. , Levi, Jessica R.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | August 3, 2021 | Volume: 166 | Issue: 3 | Pages: 413-416

10.1177/01945998211033237 | PMID 34340617 Get It

Otolaryngology is a small and highly sought‐after surgical subspecialty with sparse residency positions, making it competitive to match into. Allopathic (MD) students without home otolaryngology residency programs, osteopathic (DO) medical students, and underrepresented minorities have historically faced additional challenges in matching into otolaryngology. These specific populations generally experience limited opportunities in establishing mentors, engaging in scholarly activity, and gaining early exposure to clinical settings. Even though the American Osteopathic Association and the Accreditation Council for Graduate Medical Education merger was in part established to create equity among applicants, there remains a substantial disparity among the match rates of medical students of various educational and cultural backgrounds. The National Otolaryngology Interest Group is a student‐led interest group created to provide all medical students, especially those facing barriers, with the resources needed to best prepare for matching into an otolaryngology residency program and ultimately a career in otolaryngology.